A carregar...
Lutetium Lu-177 Dotatate Flare Reaction
PURPOSE: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors...
Na minha lista:
| Publicado no: | Adv Radiat Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811111/ https://ncbi.nlm.nih.gov/pubmed/33490736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2020.11.008 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|